Literature DB >> 16431247

Complement factor H-associated atypical hemolytic uremic syndrome in monozygotic twins: concordant presentation, discordant response to treatment.

Jean-Claude Davin1, Karolien H Olie, René Verlaak, Flore Horuz, Sandrine Florquin, Jan J Weening, Jaap W Groothoff, Lisa Strain, Timothy H J Goodship.   

Abstract

Hemolytic uremic syndrome not associated with diarrhea (diarrhea negative, atypical) is less common than the diarrhea-positive typical form, but frequently results in end-stage renal failure. Although there are anecdotal cases of successful treatment with fresh frozen plasma alone, the value of this treatment compared with plasma exchange (PE) is difficult to assess. We describe monozygotic female twins who presented at 5 years of age with factor H-related (c.3572 > T; Ser1191Leu) atypical hemolytic uremic syndrome within months of each other. In the first twin to present, 10 sessions of PE with fresh frozen plasma replacement (40 mL/kg) resulted in resolution of hemolysis and improvement in plasma creatinine level (1.9 to 1.5 mg/dL [166 to 137 micromol/L]). Subsequently, 17 infusions of fresh frozen plasma were administered during a 4-month period for recurrent thrombocytopenia. However, within 4 months, plasma creatinine level increased to 5.1 mg/dL (450 micromol/L), necessitating peritoneal dialysis. When the second twin presented with the same disease, an extended PE regimen was instituted. After 10 daily sessions, PE was continued once every 2 weeks. Two recurrences were treated successfully with daily PE for 7 days. After 44 months of follow-up, kidney function is normal (plasma creatinine, 0.6 mg/dL [53 micromol/L]; creatinine clearance, 119 mL/min/1.73 m2 [1.98 mL/s/1.73 m2]) on maintenance PE therapy. In conclusion, the response to treatment of these monozygotic twins suggests that long-term PE may have benefits over plasma infusion alone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16431247     DOI: 10.1053/j.ajkd.2005.11.007

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  14 in total

1.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

2.  Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera.

Authors:  Richard B Pouw; Mieke C Brouwer; Marlon de Gast; Anna E van Beek; Lambertus P van den Heuvel; Christoph Q Schmidt; Arie van der Ende; Pilar Sánchez-Corral; Taco W Kuijpers; Diana Wouters
Journal:  Blood Adv       Date:  2019-02-26

3.  Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.

Authors:  Gema Ariceta; Nesrin Besbas; Sally Johnson; Diana Karpman; Daniel Landau; Christoph Licht; Chantal Loirat; Carmine Pecoraro; C Mark Taylor; Nicole Van de Kar; Johan Vandewalle; Lothar B Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-09-18       Impact factor: 3.714

4.  Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations.

Authors:  Jon Jin Kim; Tim H J Goodship; Jane Tizard; Carol Inward
Journal:  Pediatr Nephrol       Date:  2011-06-30       Impact factor: 3.714

5.  Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome.

Authors:  Anne-Laure Lapeyraque; Véronique Frémeaux-Bacchi; Pierre Robitaille
Journal:  Pediatr Nephrol       Date:  2010-12-15       Impact factor: 3.714

6.  Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate.

Authors:  Hee Yeon Cho; Byong Sop Lee; Kyung Chul Moon; Il Soo Ha; Hae Il Cheong; Yong Choi
Journal:  Pediatr Nephrol       Date:  2007-02-13       Impact factor: 3.714

Review 7.  aHUS caused by complement dysregulation: new therapies on the horizon.

Authors:  Aoife M Waters; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2010-06-18       Impact factor: 3.714

Review 8.  Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.

Authors:  M Noris; G Remuzzi
Journal:  Clin Exp Immunol       Date:  2007-12-07       Impact factor: 4.330

9.  Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations.

Authors:  Anne-Laure Lapeyraque; Eric Wagner; Véronique Phan; Marie-José Clermont; Aïcha Merouani; Véronique Frémeaux-Bacchi; Timothy H J Goodship; Pierre Robitaille
Journal:  Pediatr Nephrol       Date:  2008-04-19       Impact factor: 3.714

10.  Severe atypical HUS caused by CFH S1191L--case presentation and review of treatment options.

Authors:  Sudarsana De; Aoife M Waters; Audrey O Segal; Agnes Trautmann; Elizabeth A Harvey; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2009-10-24       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.